Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

A diary entry of a North Korean soldier deployed to fight in the Russia-Ukraine war has revealed how Pyongang's troops are being used as "drone bait", as "cannon fodder" in the brutal war. Wall ...

Growth stocks are getting hammered by soaring bond yields. First off, long-dated bond yields have taken a wrecking ball to ...

His influence is partly the result of a very online political establishment, and partly thanks to a right-leaning media that is hostile to Keir Starmer’s Labour government. By Mark Landler The ...